QUOTED. 20 April 2021. Prescience Point Capital.
Executive Summary
In a scathing letter to fellow MiMedx Group shareholders, Prescience Point Capital took credit for some of the company’s recent success while also accusing the regenerative medicine company’s current board of hurting shareholder value.
“Since 2018, we believe that we have played a vital role in helping MiMedx to not only survive the financial and reputational fallout created by its accounting scandal – but also to transform itself into a much stronger company that is better positioned for sustained success.” – Prescience Point Capital
Click here for a free trial of Medtech Insight